PINK - ETF AI Analysis
Top Page
Simplify Health Care ETF (PINK)
PINK, the Simplify Health Care ETF, has a solid but not top-tier rating, reflecting a mix of strong healthcare leaders and a few more challenged holdings. High-quality names like Johnson & Johnson and United Therapeutics support the fund with robust financial performance, positive earnings calls, and strategic growth initiatives, while weaker positions such as Avantor and Warby Parker, which face profitability, valuation, and momentum concerns, likely weigh on the overall rating. The main risk is the fund’s focus on the healthcare sector, which can be sensitive to regulatory changes and industry-specific pressures.
PINK vs. SPDR S&P 500 ETF (SPY)
- AUM
- 344.54M
- Region
- North America
- Expense Ratio
- 0.51%
- Beta
- 0.65
- Issuer
- Simplify
- Inception Date
- Oct 07, 2021
- Dividend Yield
- 0.75%
- Asset Class
- Equity
- Index Tracked
- No Underlying Index
PINK Summary
PINK is the Simplify Health Care ETF, focused on the U.S. health care theme rather than tracking a specific index. It invests in a wide mix of health-related companies, including drug makers, biotech firms, medical device makers, and health insurers. Well-known holdings include Johnson & Johnson, Eli Lilly, AbbVie, and UnitedHealth. Someone might invest in PINK to tap into long-term growth driven by aging populations, new treatments, and rising demand for medical services, while getting diversification across many health care names. A key risk is that it is heavily concentrated in the health care sector, so its value can go up or down based on health care industry trends.
How much will it cost me?
This ETF has an expense ratio of 0.51%, which means you’ll pay about $5.10 per year for every $1,000 invested. That’s higher than the average low-cost index ETF because PINK is more actively managed and focused on a specialized health care sector.
What would affect this ETF?
PINK is heavily focused on U.S. health care companies like Johnson & Johnson, Eli Lilly, and UnitedHealth, so it could benefit from ongoing medical innovation, an aging population, and stable or increased health care spending. On the negative side, changes in government health policies, drug pricing rules, or insurance reimbursement, as well as broader economic slowdowns that pressure health care budgets, could hurt the fund’s future performance.
PINK Top 10 Holdings
PINK is a pure play on U.S. health care, and its story is being written mostly by a handful of big, rising names. Managed care giants like Humana and UnitedHealth have been climbing, giving the fund a solid backbone, while drugmakers such as Johnson & Johnson, AbbVie, and Eli Lilly add steady, research-driven growth. United Therapeutics and Thermo Fisher bring a more innovative, biotech-and-tools flavor that’s also been supportive. On the flip side, smaller players like Avantor and Warby Parker are lagging, slightly tugging at the fund’s otherwise upbeat health care tilt.
| Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
 ARQT | Arcutis Biotherapeutics | 7.48% | $25.37M | $4.03B | 23.51% | 60Neutral |
 JNJ | Johnson & Johnson | 7.42% | $25.17M | $657.68B | 43.25% | 78Outperform |
 HUM | Humana | 7.40% | $25.11M | $49.77B | 47.53% | 69Neutral |
 UTHR | United Therapeutics | 6.62% | $22.46M | $25.68B | 33.83% | 79Outperform |
 LLY | Eli Lilly & Co | 5.40% | $18.32M | $1.33T | 63.52% | 72Outperform |
 ABBV | AbbVie | 5.14% | $17.43M | $521.11B | 32.47% | 66Neutral |
 TMO | Thermo Fisher | 4.57% | $15.48M | $257.71B | 20.31% | 72Outperform |
 UNH | UnitedHealth | 4.54% | $15.41M | $365.29B | 17.24% | 72Outperform |
 AVTR | Avantor | 4.18% | $14.16M | $10.88B | 32.06% | 48Neutral |
 WRBY | Warby Parker | 4.15% | $14.06M | $3.04B | 21.80% | 60Neutral |
PINK Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For PINK, the sentiment is Positive. The current price of 40.08 is above the 20-day moving average (MA) of 39.05, above the 50-day MA of 39.02, and above the 200-day MA of 37.22, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 57.72 is Neutral, neither overbought nor oversold. The STOCH value of 73.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for PINK.
PINK Peer Comparison
Comparison Results
| Name | Price | Price Target | AUM | Expense Ratio | Overall Rating |
|---|---|---|---|---|---|
| PINK | $40.08 | $41.00(2.30% Upside) | $344.54M | 0.51% | 65Neutral |
 GTOP | $45.92 | $63.29(37.82% Upside) | $682.19M | 0.65% | 73Outperform |
 IETC | $99.45 | $144.09(44.89% Upside) | $639.11M | 0.18% | 74Outperform |
 IYRI | $47.01 | $53.08(12.91% Upside) | $303.47M | 0.68% | 69Neutral |
 WELD | $50.55 | $65.09(28.76% Upside) | $252.50M | 0.75% | 74Outperform |
 LFSC | $43.27 | $67.40(55.77% Upside) | $125.43M | 0.54% | 51Neutral |
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| PINK | Simplify Health Care ETF | 40.08 | 7.67 | 23.68% | |
| GTOP | Goldman Sachs Technology Opportunities ETF | 45.92 | 5.92 | 14.80% | |
| IETC | iShares Evolved US Technology ETF | 99.45 | -4.69 | -4.50% | |
| IYRI | NEOS Real Estate High Income ETF | 47.01 | 2.71 | 6.11% | |
| WELD | Tema U.S. Manufacturing & Reshoring ETF | 50.55 | 7.40 | 17.15% | |
| LFSC | F/M Emerald Life Sciences Innovation ETF | 43.27 | 11.48 | 36.11% |
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.